Meet Alfa Cytology at the Cancer R&D 2024, Nov 18-20, 2024. We look forward to connecting with you and providing expert solutions for your cancer drug development projects.
Learn More
Alfa Cytology is dedicated to developing innovative treatments for leukemia. We aim to serve pharmaceutical research companies and research institutions with our innovative leukemia animal models and professional drug development experience. Our drug development platform provides you with perfect preclinical solutions.
The surface antigens found on leukemia cells play a crucial role in the diagnosis, classification, and treatment of this disease. These antigens refer to specific proteins or glycoproteins present on the surface of leukemia cells. They serve as markers aiding in the identification and differentiation of various types of leukemia, as well as guiding the selection of treatment approaches.
Fig. 1. Surface antigens involved in leukemic stem cells (LSC) identification. (Arnone, M. et al., 2020)
Cell surface antigens (CSA) are proteins or glycoproteins located on the external membrane of cells. They play a crucial role in identifying and differentiating cell types, aiding immune recognition, and serving as binding sites for antibodies, viruses, and bacteria. Alfa Cytology provides comprehensive CSA-related development services, including but not limited to the following.
At Alfa Cytology, we specialize in providing comprehensive preclinical research services to researchers and pharmaceutical companies, including services based on leukemia cell surface antigens. The services we provide include, but are not limited to, the following targets.
| CSA | Description |
|---|---|
| CD19 | CD19 serves as a crucial marker for the B-cell lineage and is almost universally expressed in newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL). |
| CD20 | B-cell precursor acute lymphoblastic leukemia (BCP-ALL) exhibits variable expression of CD20, which is a B-cell differentiation antigen. |
| CD22 | The majority (60-90%) of B-cell acute lymphoblastic leukemia (B-ALL) blasts express CD22. |
| CD25 | CD25 is expressed on leukemic cells in 10-20% of acute myeloid leukemia (AML) cases and is associated with a poor prognosis. |
| CD30 | CD30 expression is frequently observed in virus-infected cells, such as those infected with human T-cell leukemia virus type 1 (HTLV-1). |
| CD33 | CD33 is almost universally present in acute promyelocytic leukemia (APL). |
| CD37 | CD37 demonstrates high expression in all types of B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia, and other leukemias. |
| CD38 | CD38, a transmembrane glycoprotein, is expressed on the surface of leukemic cells in a significant proportion of patients with B-cell chronic lymphocytic leukemia (B-CLL). |
| CD52 | CD52 plays a significant role in chronic lymphocytic leukemia (CLL). |
| CD123 | CD123, a membrane protein, is expressed in approximately 80% of AML cases and leukemia stem cells, and its expression is closely associated with the prognosis of AML patients. |
The surface antigens of leukemia cells play a vital role in the diagnosis, classification, monitoring of minimal residual disease, and targeted therapy of leukemia. We offer the following range of services:
Surface Antigen Detection and Identification
Using advanced immunocytochemistry and flow cytometry techniques, we perform surface antigen detection and identification on leukemia cell samples. We accurately identify and quantify the expression of target antigens, helping you determine leukemia subtypes or subclasses and providing foundational data for further research.
Minimal Residual Disease Monitoring
We provide minimal residual disease (MRD) monitoring method development services, assessing treatment efficacy and predicting relapse risk by detecting the presence and quantity of leukemia cell surface antigens. We have developed assays that are highly sensitive and accurate to help you get better results.
Targeted Therapy Strategies
Our team specializes in studying leukemia cell surface antigens and provides support for the development of targeted therapy strategies. Based on your research needs, we provide services for the development of small molecule inhibitors, antibodies, cell therapy, and vaccines, accelerating the drug discovery process.
Biomarker Development Services
Through validation studies on leukemia models, we will evaluate the potential value of specific Cell Surface Antigens as biomarkers for you. These services include analyzing their expression patterns in different subtypes of leukemia and their associations with disease progression and prognosis.
At Alfa Cytology, whether you represent an academic institution or a pharmaceutical company, our primary goal is to deliver tailored preclinical research services to meet your specific requirements. We prioritize the quality of data, confidentiality, and timely project delivery, while working closely with you to ensure the success of your research endeavors. If you are intrigued by our preclinical research services or have any inquiries, please feel free to reach out to us at your convenience.
Reference